Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL1207
- Development stage
- Phase 3
- Lead developer
- Qilu Pharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
QL1207 is a biosimilar to aflibercept, developed by Qilu Pharmaceutical for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). It is administered as an intravitreal injection. QL1207 acts as an inhibitor of vascular endothelial growth factor A (VEGF-A) and placenta growth factor, thereby reducing abnormal blood vessel growth and leakage in the retina. Clinical trials have demonstrated that QL1207 has equivalent efficacy, safety, immunogenicity, and pharmacokinetic profiles compared to reference aflibercept in patients with nAMD. It represents the first approved aflibercept biosimilar in China[1][2][4][5][6][7].
- Other names
- aflibercept biosimilar
02
Targets
PGF (Placental Growth Factor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on QL1207.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL1207.